Clinical Trials Directory

Trials / Completed

CompletedNCT02661178

First in Man Clinical Trial of Emodepside (BAY 44-4400)

A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
79 (actual)
Sponsor
Drugs for Neglected Diseases · Academic / Other
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers. This study will also conduct an exploratory investigation of the relative bioavailability of emodepside administered as tablets and determine the effect of food on the pharmacokinetics.

Conditions

Interventions

TypeNameDescription
DRUGemodepside (BAY 44-4400)
DRUGplacebo

Timeline

Start date
2015-12-01
Primary completion
2017-03-27
Completion
2017-03-27
First posted
2016-01-22
Last updated
2020-04-13
Results posted
2020-04-13

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02661178. Inclusion in this directory is not an endorsement.

First in Man Clinical Trial of Emodepside (BAY 44-4400) (NCT02661178) · Clinical Trials Directory